跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLYXAMBI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
GLYXAMBI
Authorized
STANDARD
GLYXAMBI
boehringer ingelheim (canada) ltd ltee
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
27731de8ec99f4b3
Company
boehringer ingelheim (canada) ltd ltee
Type
Standard
Approval Details
Approval Id
27731de8ec99f4b3
Drug Approval Canada Name
GLYXAMBI
Product Name
GLYXAMBI
Status
Cancelled Post Market
Status Date
2021-12-09
Original Market Date
2016-12-21
Din
02459760
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.05
Atc Original
A10BD19 LINAGLIPTIN AND EMPAGLIFLOZIN
Atc Name
a 10 bd 19
Aig Number
0258690002
Company Name
boehringer ingelheim (canada) ltd ltee
Company Address
5180 South Service Road, Burlington, Ontario, Canada, L7L 5H4
Active Ingredients
LINAGLIPTIN
5 MG
EMPAGLIFLOZIN
25 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
27731de8ec99f4b3
Type
Standard
Back to Health Canada Approvals